Danish biosolutions and biotechnology company Novonesis announced a ₹6,660 crore investment to expand its facility at Patalganga in Maharashtra to build an advanced enzyme production facility. According to reports from Business Standard, the facility is expected to be fully operational by 2030 and will produce enzymes for a broad range of industries, including biofuels, household care, and food and beverages. The expansion is aimed at increasing the company's production capacity to meet growing global demand for biosolutions. As per Novonesis, the investment will strengthen the company's ability to support customers around the world and enable it to continue creating long-term value for shareholders.
The expanded facility will help Novonesis meet increasing demand from emerging markets, including those in the Middle East, Africa, India and South Asia. As reported by Business Standard, the company's president and chief executive Ester Baiget stated that these markets represent an important and growing part of the company's business and are expected to grow faster than developed markets in the coming years. According to Novonesis, the Patalganga expansion will strengthen the company's scale, operational resilience, efficiency, and supply flexibility, enabling it to serve customers in key growth markets more effectively and support its long-term growth targets. The facility will form part of Novonesis' global production network and bring the company closer to customers in these key emerging markets.
The Patalganga facility will get Novonesis closer to customers and help strengthen its scale, operational resilience, efficiency, and supply flexibility. According to Business Standard, the company has committed that the new facility will use less water and energy, with freshwater recycling reducing the amount of water the site draws and integrated heat pumps lowering the energy required to operate it. As per Novonesis Chief Operating Officer Anders Lund, the investment would also enable the company to serve customers in key growth markets more effectively and support its long-term growth targets. The facility will be integrated into the company's global production footprint and enable the company to continue creating long-term value for shareholders.
The Patalganga plant was first commissioned in 2019 by Novozymes, which was merged with Chr. Hansen to create Novonesis in 2024. As reported by Business Standard, the facility is located on the outskirts of the financial capital and houses a slew of chemical and petrochemical units, including Reliance Industries' first plant and facilities by Hindustan Organic Chemicals, Cipla and Asian Paints, among others. The investments align with the company's strategy and previously communicated capital expenditure plans, with Krishna Mohan Puvvada, Regional President, Middle East, India & Africa, noting that the investment will support long-term growth ambitions and position the company strongly to advance India's growing bioeconomy. Puvvada highlighted that with the launch of the BioE3 policy by the Government of India, the country has taken transformative steps to unlock the true economic, social, and environmental potential of biosolutions for a net-zero carbon future.
